Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.60 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534947 | 1.00 | CHRNA7 (0.71) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL3591843 | 1.00 | CHRNA7 (0.71) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL7878453 | 0.90 | CHRNA7 (0.65) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL30077049 | 0.90 | CHRNA7 (0.65) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL7878773 | 0.90 | CHRNA7 (0.65) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL30077103 | 0.90 | CHRNA7 (0.65) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL7878455 | 0.90 | CHRNA7 (0.65) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL20137193 | 0.86 | CHRNA7 (0.80) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL5899579 | 0.86 | CHRNA7 (0.80) | CHRNA7OPRM1OPRK1OPRL1OPRD1 | |
| SCHEMBL10544549 | 0.85 | CHRNA7 (0.67) | CHRNA7OPRM1OPRK1OPRL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2128154-B1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-04-08 | — | — | EP | disclosed |
| US-8877779-B2 | Benzimidazole compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-2128154-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-12-02 | — | — | EP | disclosed |
| EP-0963987-B1 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | HOFFMANN LA ROCHE (CH) | 2002-08-28 | — | — | EP | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| US-6075034-A | Spiro[piperidine-4,1'-pyrrolo [3,4-C] pyrrole]derivatives | HOFFMANN-LA ROCHE INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-6071925-A | ANTIDEPRESSANTS, ANTICONVULSANTS OR ANTIANXIETY AGENTS, ALSO FOR TREATMENT OF MEMORY LOSS IN ALZHEIMER'S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0963987-A2 | Spiro(piperidine-4,1'-pyrrolo(3,4-c)pyrrole) | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120841-A1 | BENZIMIDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | ORMDL3, OXA1L, OGFRL1 | CHRNA7 1090/4885OPRM1 55/4885OPRK1 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.